Fulcrum Q2 net loss $17.3M; pociredir Phase 1b shows HbF increase 8.6% in SCD

Fulcrum Therapeutics, Inc.

2025-Q2 EPS reported -$0.56

Q2 2025 net loss $17.3M vs net income $55.4M in Q2 2024; cash $214.1M, runway into 2028.
Phase 1b 12 mg cohort: mean HbF increased 8.6% (7.6% to 16.2%); 7/16 patients achieved >20% HbF.
Hemolysis markers improved: indirect bilirubin -37%, LDH -28%, reticulocyte -30%; total hemoglobin +0.9 g/dL.
Safety: pociredir generally well-tolerated, no drug-related SAEs, all treatment-related AEs Grade 1.
20 mg cohort ongoing; data expected by end of 2025; IND for DBA planned Q4 2025.

item 2.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.